Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.
10.4070/kcj.2013.43.8.557
- Author:
Soonyoung PARK
1
;
Jooyoung LEE
;
Sang Yeub LEE
;
Jang Whan BAE
;
Kyung Kuk HWANG
;
Dong Woon KIM
;
Myeong Chan CHO
;
Sang Min KIM
Author Information
1. Regional Cardiovascular Center, Division of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea. sangmin3410@gmail.com
- Publication Type:Case Report
- Keywords:
Thrombocytopenia;
Abciximab;
No-reflow phenomenon
- MeSH:
Acute Coronary Syndrome;
Antibodies, Monoclonal;
Humans;
Immunoglobulin Fab Fragments;
Myocardial Infarction;
No-Reflow Phenomenon;
Percutaneous Coronary Intervention;
Shock, Cardiogenic;
Thrombocytopenia
- From:Korean Circulation Journal
2013;43(8):557-560
- CountryRepublic of Korea
- Language:English
-
Abstract:
Glycoprotein IIb/IIIa antagonists are well established for their effectiveness in improving clinical outcomes in acute coronary syndrome patients undergoing percutaneous coronary intervention. Acute profound thrombocytopenia is a rare complication of abciximab. We present a case which was managed successfully for the rare complication of acute profound thrombocytopenia after using abciximab and an intra-aortic balloon pump for the treatment of a no-reflow phenomenon and consecutive cardiogenic shock during primary percutaneous coronary intervention.
